These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36649539)

  • 1. Metabolism and pharmacokinetic study of deuterated osimertinib.
    Zhan X; Bao S; Li X; Zhou S; Dahar MR; Lin N; Chen X; Niu C; Ji K; Wu Y; Zeng K; Tang Z; Yu L
    Biopharm Drug Dispos; 2023 Apr; 44(2):165-174. PubMed ID: 36649539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
    Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
    Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
    Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
    Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.
    Meng Y; Yu B; Huang H; Peng Y; Li E; Yao Y; Song C; Yu W; Zhu K; Wang K; Yi D; Du J; Chang J
    J Med Chem; 2021 Jan; 64(2):925-937. PubMed ID: 33459024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
    van Veelen A; Gulikers J; Hendriks LEL; Dursun S; Ippel J; Smit EF; Dingemans AC; van Geel R; Croes S
    Lung Cancer; 2022 Sep; 171():97-102. PubMed ID: 35933915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
    Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
    Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
    Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats.
    Wu Q; Jiang H; Wang S; Dai D; Chen F; Meng D; Geng P; Tong H; Zhou Y; Pan D; Zhou Q; Wang C
    Thorac Cancer; 2020 Oct; 11(10):2775-2781. PubMed ID: 32812378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy.
    MacLeod AK; Lin D; Huang JT; McLaughlin LA; Henderson CJ; Wolf CR
    Clin Cancer Res; 2018 May; 24(9):2138-2147. PubMed ID: 29437786
    [No Abstract]   [Full Text] [Related]  

  • 10. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
    J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
    Harvey RD; Aransay NR; Isambert N; Lee JS; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K; Thomas K; Vishwanathan K
    Br J Clin Pharmacol; 2018 Dec; 84(12):2877-2888. PubMed ID: 30171779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
    Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.
    Wang Z; Wang X; Wang Z; Jia Y; Feng Y; Jiang L; Xia Y; Cao J; Liu Y
    Toxicol Lett; 2021 Sep; 348():10-17. PubMed ID: 34044055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
    Li L; Wang Y; Jiao L; Lin C; Lu C; Zhang K; Hu C; Ye J; Zhang D; Wu H; Feng M; He Y
    Cancer Lett; 2019 Jun; 452():191-202. PubMed ID: 30910592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
    Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
    Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
    Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
    Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.